RE: Take Over25 Feb 2022 09:34
"SNG will not agree anything"
It's not entirely up to them. Polygon's stake is key. If a big pharma saw enough in the data to think it might be worth something with proper development, and made a bid at, say, 60p, and Polygon accepted, I think more than 1/3 of remaining shareholders might be glad to get something back. I don't think Polygon want to hang around for A2P3.